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Abstract Ghrelin is a hormone that regulates appetite. It is
likely to be involved in the pathophysiology of varying forms
of diabetes. In animal studies, the ghrelin expression was
regulated by the hepatocyte nuclear factor 1 alpha (HNF1A).
Mutations of the HNF1A gene cause maturity onset diabetes
of the young (MODY). We aimed to assess the circulating
ghrelin levels in HNF1A–MODY and in other types of dia-
betes and to evaluate its association with HNF1A mutation
status. Our cohort included 46 diabetic HNF1A gene muta-
tion carriers, 55 type 2 diabetes (T2DM) subjects, 42 type 1
diabetes (T1DM) patients, and 31 glucokinase (GCK) gene
mutation carriers with diabetes as well as 51 healthy controls.
Plasma ghrelin concentration was measured using the im-
munoenzymatic assay with polyclonal antibody against the
C-terminal fragment of its acylated and desacylated forms.
Ghrelin concentrations were 0.75 ± 0.32, 0.70 ± 0.21,
0.50 ± 0.20, and 0.40 ± 0.16 ng/ml in patients with
HNF1A–MODY, GCK–MODY, T1DM, and T2DM, re-
spectively. The ghrelin levels were higher in HNF1A–
MODY and GCK–MODY than in T1DM and T2DM
(p\ 0.001 for all comparisons) but lower than in non-
diabetic controls (1.02 ± 0.29 ng/ml, p\ 0.001 for both
comparisons). In the multivariate linear model, the
differences between both MODY groups and common dia-
betes types remained significant. Analysis by a HNF1A
mutation type indicated that ghrelin concentration is similar
in patients with different types of sequence differences.
Plasma ghrelin level is higher in HNF1A–MODY and GCK–
MODY than in the common polygenic forms of diabetes.
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Introduction
Monogenic diabetes accounts for only a small portion of
diabetes cases; however, a proper differential diagnosis
usually brings substantial clinical benefits for the subjects
affected by a single gene form of this disease. Monogenic
diabetes is caused by a mutation in one of about a dozen of
genes. One of the most common is the defect of the HNF1A
(Hepatic Nuclear Factor 1A) gene, that accounts for ap-
proximately a half of all cases of maturity onset diabetes of
the young (MODY). MODY is characterized by early
disease onset and an autosomal dominant mode of in-
heritance [1]. HNF1A is a transcription factor that controls
b-cell development, mass, and function. It is also expressed
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in digestive tract, liver, and kidneys participating in the
regulation of a wide number of genes [2, 3].
In the recent studies, HNF1A protein was shown as an
upstream regulator of several neuroendocrine peptides.
Among them, ghrelin, a peptide hormone the amino acid
sequence of which is highly conserved among mammals,
was identified as one of the targets [4]. Ghrelin is secreted
mostly by stomach but is also widely expressed in the other
locations, including pancreatic cells. It stimulates appetite
and regulates secretion of other hormones, such as growth
hormone, glucagon, and insulin [5]. Ghrelin is a non-gly-
cosylated peptide, which is present in the bloodstream in
two major molecular forms: desacylated and acylated. The
desacylated molecular form accounts for 90 % of the cir-
culating ghrelin. Acylated ghrelin was considered to be the
only metabolically active form of ghrelin peptide acting as
a mediator in metabolic, hormonal, and inflammation
processes in humans [6]. However, recent studies have
showed that desacylated ghrelin is also functionally active;
however, its metabolic role has not yet been defined
[7–10].
In vitro studies have shown that HNF1A interacts with
specific binding sites of the ghrelin gene promoter and
suppresses hormone expression [11]. In the experimental
animals, ghrelin mRNA level was increased by
approximately five-fold in homozygous HNF1A knock-out
mice as compared to the wild type [11, 12]. This was
further followed by five-fold higher concentration of the
total and active forms in serum and, interestingly, by a
subsequent decrease of insulin level. Consistent with these
findings, a targeted silencing of HNF1A gene expression in
the pancreatic endocrine cell line induced ghrelin gene
transcript [12].
Taken together, the body of evidence shows that
HNF1A acts as a repressor of ghrelin secretion through a
direct effect on its promoter. So far, the ghrelin level in
human HNF1A gene mutation carriers or other MODY
subjects has not been examined, while data from type 1
(T1DM) and type 2 diabetes (T2DM) are limited. The
primary aim of this study was to compare plasma ghrelin
level in HNFA1–MODY with glucokinase (GCK)–MODY,
T1DM, and T2DM subjects as well as non-diabetic healthy
individuals. Additionally, we evaluated plasma ghrelin as a
biomarker of HNF1A mutation status.
Materials and methods
Study population
The studied group included 46 HNF1A–MODY indi-
viduals, 31 GCK gene mutation carriers with diabetes, 55
T2DM subjects, and 42 T1DM patients. In addition, 51
healthy non-carrier individuals were recruited from the
families of patients with MODY, as the reference group.
All MODY cases had a heterozygous loss-of-function
mutation either in the HNF1A or GCK gene identified by
direct DNA sequencing. For further analysis, the mutations
within HNF1A gene were classified with respect to their
type as either protein-changing (related to a missense
change of amino acid) or truncating (resulting in a pre-
mature stop codon) mutations and according to the affected
functional domain (dimerization/DNA-binding domain, or
transactivation domain) [13, 14]. We included patients with
clinical diagnosis of T2DM only if they had a disease
detected below the age of 45 years, so that rough age
matching could be performed and had no insulin treatment
for at least 2 years after the initiation of pharmacotherapy,
which were the criteria we used in our previous research to
differentiate T2DM patients from subjects with autoim-
mune diabetes [15]. Subjects with T1DM were ascertained
if at diagnosis they had typical clinical symptoms, insulin
therapy requirement from the beginning of the disease, and
diabetes diagnosed below 30 years of age. For all study
subjects, we collected data on their clinical characteristics
and determined ghrelin levels in plasma specimens. We
excluded subjects with chronic kidney disease (defined as
CKD-EPI GFR\60 ml/min/1.73 m2), individuals on ster-
oid therapy, and pregnant women. The protocol of the
study was approved by the Bioethical Committee of the
Jagiellonian University and all subjects gave written
informed consent.
Ghrelin measurement
We used ghrelin specific immunoenzymatic assay (Phoenix
Pharmaceuticals, Belmont, CA) that recognizes the C-ter-
minal part of ghrelin peptide chain. As the literature sug-
gested that sample pretreatment might influence the
N-terminal fragment stability, the C-terminal based kit was
used [16]. This one-site assay determines both intact
ghrelin and some of its more stable breakdown products.
The lower and upper limits of quantification for this assay
were 0.11 and 1.60 ng/ml, respectively. The other valida-
tion parameters of the assay such as lower limit of quan-
tification, linearity of the dilution, and cross-reactivity have
already been reported by the manufacturer. The measure-
ments were performed in specimens collected after at least
8-h fasting. Venous blood was drawn into EDTA tubes.
Samples were stored at 4 C during the collection period
and then centrifuged at 4 C. The plasma was separated
into aliquots and then stored at -40 C until assayed. All
assays included control samples which were collected at
the beginning of the study, transferred to aliquots, and used
to test for assay variability. Based on these, the intra-assay
and inter-assay coefficients of variation (CV) were 6 and
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22 %, respectively. The diabetic subgroups were repre-
sented equally in each plate.
Statistical analysis
The computations were made with SAS, Version 9.3 (SAS
Institute, Cary, NC), and MedCalc, Version 12.1.4 (MedCalc
Software, Mariakerke, Belgium). P values for testing dif-
ferences across groups were calculated with one-way
ANOVA followed by Tukey’s post hoc test. The comparison
of categorical variables was done by v2 test. We assessed if
MODY predicted ghrelin concentration using linear regres-
sion models, with type of diabetes as the explanatory vari-
able. The clinical factors (age of examination, diabetes
duration, BMI, gender, treatment with insulin, HbA1c con-
centration) were individually tested as predictors and then
were analyzed in multiple linear regression models with
backward selection of covariates. The variables kept in the
model were further used as basic model for ghrelin at testing
differences between various diabetic subgroups; group pre-
sented as ordinal variable was added into general linear
model, to test independence from other ghrelin predictors.
The potential of co-linearity was assessed by variance in-
flation factors (VIF), with VIF less than 10 considered as
acceptable. To control for the extent of degradation of the
analyte, we also included length of storage, defined as the
time between blood collection and assay determination, as a
covariate in additional regression analysis. Including this
variable did not affect the study results. Diagnostic perfor-
mance (i.e., the ability of ghrelin to identify HNF1A–MODY
and GCK–MODY) was assessed using the receiver operating
characteristics (ROC) curve. The standard error (SE) of the
area under the ROC curve (AUC) and 95 % confidence in-
tervals (95 % CI) were calculated using the method de-
scribed by DeLong et al. [17]. All tests were two-tailed, and
p value\0.05 was considered significant.
Results
The study groups’ clinical characteristics and biochemical
measurements are summarized in Table 1. No significant
differences were observed between the HNF1A–MODY,
GCK–MODY, and T1DM in terms of age, sex distribution,
and body mass index (BMI). Patients in T2DM group were
significantly older, more obese, and had later diabetes onset
than MODY subjects, which is in line with the way the
groups were defined. Also, patients with common form of
diabetes demonstrated worse glycemic control than indi-
viduals with MODY, as assessed by the fasting glucose and
HbA1c levels.
The distribution of crude values of ghrelin in the study
groups is shown in Fig. 1. Mean concentration in HNF1A–
MODY subjects was 0.75 ng/ml (SD = 0.32 ng/ml). It was
approximately twofold higher than in the T2DM group
(0.40 ± 0.16 ng/ml; p\ 0.001) and 50 % higher than in the
T1DM group (0.50 ± 0.20 ng/ml; p\ 0.001). Ghrelin level
was lower in all diabetic subjects than in the healthy controls
(1.02 ± 0.29 ng/ml, p\ 0.001). Ghrelin level was also
lower in HNF1A–MODY and in GCK–MODY as compared
to non-diabetics (p\ 0.001 for both comparisons). No
measurable differences were observed between the crude
ghrelin concentrations in HNF1A–MODY and GCK–
MODY (0.70 ± 0.21 ng/ml; p = 0.36), that similarly pre-
sented higher levels in comparison to T1DM (p\ 0.001)
and T2DM (p\ 0.001).
In the HNF1A–MODY group, ghrelin level significantly
correlated with age at examination (q = -0.39, p = 0.008),
diabetes duration (q = -0.30,p = 0.05), and was marginally
correlated with BMI (q = -0.25,p = 0.1), whereas in GCK–
MODY, there was a significant correlation with age (q =
-0.41, p = 0.02). In the type T2DM group, there was sig-
nificant correlation only with BMI (q = -0.44, p\ 0.001).
No significant correlation was observed, in the diabetic sub-
groups, for HbA1c, and fasting glucose level. In the analyses
conducted in pooled diabetic groups, ghrelin level correlated
inversely with BMI (q = -0.37; p\ 0.001), age at the ex-
amination (q = -0.31; p\ 0.001), and with the HbA1c level
(q = -0.31; p\ 0.001). Sex influenced ghrelin level in all
diabetic groups combined, as well as in a separate analysis of
HNF1A–MODY individuals (0.51 ± 0.26 vs. 0.64 ±
0.29 ng/ml; p = 0.001 for males and females in combined
diabetic cohort and 0.62 ± 0.25 vs. 0.82 ± 0.37 ng/ml;
p = 0.04 in the HNF1A–MODY, respectively). In multi-
variate linear regression (R2 = 25 %), only significant pre-
dictors remained BMI (p = 0.002) and age at examination
(p = 0.001). When significance (a value) was set up at 0.1
(instead of 0.05) during testing of predictors and analyzing in
multiple linear regression model, insulin treatment status was
additionally kept in the model. However, the only significant
variables were BMI and age at examination.
In a general linear model (R2 = 36 %) applied in polled
diabetic groups, the differences between HNF1A–MODY
and T1DM and between GCK–MODY and T1DM re-
mained significant; their pattern and magnitude remained
unchanged to that in univariate analysis (p\ 0.001 for
both comparisons). Group was the strongest independent
variable associated with ghrelin, the next one being age
(p = 0.004), and BMI (p = 0.01).
The ROC curves illustrating ghrelin capacity in distin-
guishing both examined MODY types and T1DM are
presented in Fig. 2. The discriminative accuracy, as ex-
pressed by AUC of ghrelin between HNF1A–MODY and
T1DM, was 0.73 (95 % CI 0.63; 0.84) with the corre-
sponding sensitivity and specificity of 74 % (95 % CI 57.2;
85) and 66.7 % (95 % CI 49.3–98.90), respectively. For
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GCK–MODY and T1DM, a slightly better result was ob-
tained (AUC = 0.77; 95 % CI 0.66; 0.89).
With the adjustment for BMI and age at examination the
ghrelin concentrations in T2DM and both MODY groups had
similar pattern but the differences were reduced by ap-
proximately 50 % as compared with crude estimates
(p = 0.007, and p = 0.005 for HNF1A–MODY and GCK–
MODY, accordingly). The covariate-adjusted AUC showed
a weak distinction between HNF1A–MODY and T2DM
(AUC = 0.70; 95 % CI 0.51–0.88), and only a slightly better
for GCK–MODY and T2DM (AUC = 0.77; 95 % CI
0.58–0.97).
We also examined the influence of the type and local-
ization of HNF1A mutation on ghrelin concentration.
Among HNF1A mutations, 22 were classified as truncating
and 24 as missense changes. While none were assigned to
DNA-binding domains, 26 were assigned to dimerization,
and 20 were assigned to transactivation domains of the
peptide. Analysis by mutation type indicated that ghrelin
concentration was circa 15 % (0.11 ng/ml) higher in
HNF1A–MODY patients with protein-changing mutations
than those with truncating mutations; however, the differ-
ence did not reached significance (p = 0.3). No measurable
difference in ghrelin concentration was found between
mutations located in DNA-binding and transactivation
domains (p = 0.97).
Discussion
Here, for the first time, we examined the plasma ghrelin
levels across several types of diabetes and in non-diabetic
controls. Our results showed that circulating ghrelin con-
centration may, at least to some degree, depend on the
etiology of diabetes.
Ghrelin plays an important regulatory role in metabo-
lism, particularly in appetite control [18]. Additionally,
Table 1 Clinical characteristics of patients and controls without diabetes
Characteristics HNF1A–MODY T1DM T2DM GCK–MODY ND P value
No. of individuals 46 42 55 31 51 NA
Female/male 27/19 21/24 19/36 17/13 28/23 0.09&
Age at examination
(years)
31.6 (27.1–36.1) 31.5 (29.2–33.9)^# 53.5 (50.5–55.7)^# 35.9 (28.7–43.2) 38.7^ \0.001*
Diabetes duration
(years)
11.2 (7.7–14.7) 8.9 (6.8–10.9)^# 13.1 (10.6–15.4)^# 5.5 (2.6–8.4) NA \0.001*
BMI (kg/m2) 22.9 (21.8–24.2) 23.6 (22.6–24.7) 31.1 (30.1–33.3)^# 24.4 (22.6–26.2) 23.3 (22.4–26.2) \0.001*
HbA1c (%) 6.7 (6.3–7.1) 8.1 (7.5–8.6)^# 8.7 (8.3–9.2)^# 6.7 (6.2–7.1 NA \0.001*
Fasting glucose
(mmol/L)
6.4 (5.6–7.1) 7.7 (7.2–8.5) 8.74 (8.3–9.3)^# 6.1 (5.1–6.9) NA \0.001*
% on insulin 36 % 100 % 63 % 26 % NA \0.001&
% on OHA 62 % 0 % 27 % 23 % NA \0.001&
Ghrelin (ng/ml) 0.75; 0.73;
(0.66–0.86)
0.50; 0.47
(0.44–0.57)
0.40; 0.40
(0.36–0.45)
0.7; 0.66
(0.62–0.78)
1.02; 1.01
(1.01–1.14)
\0.001*
Data are expressed as means and 95 % confidence intervals for the mean, except treatment, and sex proportions. Ghrelin concentration was
reported as mean, median, and 95 % for the mean
N number of individuals, BMI body mass index, HbA1c Hemoglobin A1c, OHA oral anti-hyperglycemic agents
* One-way ANOVA
& v2 test
^ P value based on Tukey post hoc test for the difference versus HNF1A–MODY\0.05
# P value based on post hoc Tukey test for testing the difference versus GCK–MODY\0.05
Fig. 1 The distribution of crude values of ghrelin level in the study
groups
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ghrelin influences insulin secretion, glucose homeostasis,
and adipogenesis processes [5, 19]. In animal models,
ghrelin expression and its peptide concentration were
higher in mice with homozygous knockout of the HNF1A
gene as compared to the wild type. However, we were not
able to confirm this in the study on human subjects, as,
contrary to the initial hypothesis of our project, ghrelin
level was lower in HNF1A–MODY caused by a
heterozygous loss-of-function mutation than in the non-
diabetic individuals. On the other hand, it was higher in
HNF1A–MODY patients (as well as GCK–MODY indi-
viduals) than in both common forms of diabetes. Interest-
ingly, in our study, ghrelin level did not differ between
HNF1A–MODY and GCK–MODY patients. For T2DM,
this difference was partly dependent on the clinical char-
acteristics of a group chosen for the comparison. In our
study and previously published reports, ghrelin correlated
negatively with BMI and age in healthy subjects as well as
diabetic individuals [20, 21]. Also, low ghrelin level in
T2DM as compared to non-diabetic controls has been
earlier attributed to the presence of chronic inflammation,
insulin resistance, and hyperinsulinemia [6, 22]. The ob-
served negative correlation between ghrelin and age is
similar to that reported from other studies in diabetic and
healthy individuals, and so is consistent ghrelin age-related
decline. Nevertheless, although T2DM patients were sig-
nificantly older than subjects from the other groups, the
observed differences persisted, although diminished, even
after adjustment for age at study entry. So far, very limited
data have been published on ghrelin concentrations in
T1DM patients. However, one study had shown that
ghrelin level was lower in the newly diagnosed T1DM
children than in the non-diabetic individuals [23]. Likewise
the T1DM children lacked proper ghrelin response to a
meal [24]. We consider that differences in levels of gly-
cemic control are among the factors potentially contribut-
ing to the observed variability in ghrelin concentration
between the examined groups. Some differences might be
also related to monogenic alterations in GCK and HNF1A
proteins, acting through different, not yet identified,
mechanisms.
An interesting facet of ghrelin pathophysiology is related
to its potential contribution to the elevated glucose level in
patients with diabetes and to its putative therapeutic use. For
example, it was shown that ghrelin contributed to the
HNF1A loss-related hyperglyceamia in rodents and the
ghrelin receptor blockade in HNF1A knockout mice led to a
recovery of diabetic symptoms [6]. It has also been
documented that ghrelin reduces glucose-induced insulin
secretion in healthy human subjects [19, 25]. The mechan-
ism of this phenomenon may involve a suppression of
insulin secretion in which ghrelin either acts directly via
activation of the b-cell growth hormone secretagogue
receptor (GHS-R1a) or indirectly through interaction with
the vagus nerve [26]. In our study, ghrelin was unrelated to
any parameters of glycemic control in stratified analysis,
while some other expected associations were present. The
potential modification of glycemic control by ghrelin in
patients with diabetes as well as the putative glucose-low-
ering mechanism related to inhibition of its pathway requires
further investigation using a different study design than ours.
As acylated and desacylated ghrelin isoforms influence
glucose homeostasis in opposite directions, their proportion
should be assessed in future studies [7–9].
Fig. 2 ROC curves illustrating discriminative performance of plasma ghrelin to distinguish between diabetic subgroups. a HNF1A MODY and
type 1 diabetes, b GCK MODY and type 1 diabetes
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Currently, most of the MODY patients remained mis-
diagnosed as T1DM or T2DM. A proper differential di-
agnosis brings a clinical benefit to the affected individuals
and their families. For example, it helps tailor more per-
sonalized treatment and define prognosis in the family.
Thus, it would be beneficial to identify cheap and easy-to-
use non-genetic markers that could be applied for screening
a wide number of subjects for different MODY subtypes
[27]. There were a few such promising biomarkers exam-
ined over the last years, such as hs-CRP, 1,5-anhydroglu-
citol, apolipoprotein M, and some others; nevertheless,
none of them have entered widely into clinical use [28, 29].
The crude ghrelin capacity for distinguishing MODY from
T1DM and T2DM was moderate; additionally, in T2DM it
was partially dependent on the variability in basic clinical
covariates that are considered in diagnostic algorithm.
Based on the results of our study, we are not able to rec-
ommend ghrelin as a robust parameter in differential di-
agnosis of MODY.
Finally, we did not identify any convincing evidence for
the possible association of type of HNF1A mutation with
the ghrelin level, although the concentration of examined
hormone tended to be higher in patients with missense
protein-changing HNF1A mutations as compared to the
ones with truncating sequence differences. Interestingly,
the type of HNF1A mutation, as reported earlier, seems to
modify levels of other circulating biomarkers, such as hs-
CRP and DG9-glycan index levels, with missense muta-
tions being related to the lower level of examined particles
[29, 30]. These results could probably be explained by a
dominant-negative effect, which was reported for some
HNF1A mutations. We also did not find any evidence for
the earlier reported relationship between the localization of
gene sequence differences on ghrelin concentration [29,
30]. This may be explained by a modest effect of HNF1A
on ghrelin in human subjects, small number of study sub-
jects in subgroups used for comparison (a shortcoming of
the current study), or by presence of the unidentified con-
founding factors [31, 32].
In summary, plasma ghrelin level seems to depend on
the etiology of diabetes and is higher in HNF1A–MODY
and GCK–MODY than in both common polygenic forms
of diabetes. However, it does not seem to be a good
biomarker in differential diagnosis of diabetes subtypes.
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